Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D7L1MP
|
|||
| Drug Name |
MEDI5752
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Non-small-cell lung cancer [ICD-11: 2C25] | Phase 1 | [1] | |
| Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199] | Phase 1 | [2] | ||
| Company |
AstraZeneca
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cytotoxic T-lymphocyte protein 4 (CTLA-4) | Target Info | Inhibitor | [3] |
| Programmed cell death protein 1 (PD-1) | Target Info | Inhibitor | [3] | |
| KEGG Pathway | Cell adhesion molecules (CAMs) | |||
| T cell receptor signaling pathway | ||||
| Autoimmune thyroid disease | ||||
| Rheumatoid arthritis | ||||
| Pathway Interaction Database | Calcineurin-regulated NFAT-dependent transcription in lymphocytes | |||
| Reactome | CTLA4 inhibitory signaling | |||
| PD-1 signaling | ||||
| WikiPathways | Vitamin D Receptor Pathway | |||
| T-Cell Receptor and Co-stimulatory Signaling | ||||
| Allograft Rejection | ||||
| Costimulation by the CD28 family | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03819465) A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC (MAGELLAN). U.S. National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT03530397) A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors. U.S. National Institutes of Health. | |||
| REF 3 | Bispecific Antibodies to PD-1 and CTLA4: Doubling Down on T Cells to Decouple Efficacy from Toxicity. Cancer Discov. 2021 May;11(5):1008-1010. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.